HLX10 + HLX07 + cisplatin + 5-fluorouracil

This is a four-drug **combination therapy for cancer**, specifically trialed for recurrent or metastatic head and neck squamous cell carcinoma (SCCHN) and esophageal squamous cell carcinoma (ESCC). It includes: - **HLX10**: a recombinant humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody, acting as an immune checkpoint inhibitor to enhance antitumor immunity[1][3][9]. - **HLX07**: a recombinant anti-epidermal growth factor receptor (EGFR) humanized monoclonal antibody, a biobetter of cetuximab, targeting EGFR overexpression in solid tumors[1][5][7][9]. - **cisplatin**: a platinum-based chemotherapy agent that forms DNA crosslinks and induces apoptosis in rapidly dividing cells[2][4][6][8][10]. - **5-fluorouracil** (5-FU): a chemotherapy agent that inhibits DNA synthesis by interfering with thymidylate synthase, affecting rapidly dividing cells[2][4][6][8][10]. HLX10 and HLX07 are developed by Shanghai Henlius Biotech, while the chemotherapy agents are widely manufactured and used. The combination is studied as first-line therapy for recurrent/metastatic SCCHN and ESCC[5][9].

Other names

HLX10 + HLX07 + cisplatin + 5-fluorouracil